Indivior director granted 3,722 RSUs

Indivior Pharmaceuticals director Daniel A. Ninivaggi received an equity grant through restricted stock units.

Rhea-AI Filing Summary

Indivior Pharmaceuticals director Daniel A. Ninivaggi received an equity grant through restricted stock units. On 01/26/2026 he was awarded 3,722 RSUs, recorded at a price of $0 per unit, increasing his beneficial ownership to 20,645 shares of common stock held directly.

The RSUs each represent a right to receive one share of Indivior common stock. They vest on the day immediately before the first annual meeting of stockholders following the grant date, as long as he continues to serve the company through that vesting date.

Insider Trade Summary

Grant/Award: 3,722 shares

Grant/Award 1 txn

Insider NINIVAGGI DANIEL A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,722	$0.00	$0.00

Holdings After Transaction: Common Stock — 20,645 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Indivior (INDV) report in this Form 4?

Indivior reported that director Daniel A. Ninivaggi received 3,722 restricted stock units on 01/26/2026. These RSUs convert into common shares at vesting, adding to his existing direct equity stake in the company.

How many Indivior (INDV) shares does the director own after this RSU grant?

After the grant, Daniel A. Ninivaggi beneficially owns 20,645 shares of Indivior common stock directly. This total includes the impact of the 3,722 restricted stock units awarded on 01/26/2026 as reported in the filing.

What are the vesting terms of the Indivior (INDV) RSUs granted to the director?

The 3,722 restricted stock units vest on the day immediately preceding the first annual meeting of Indivior stockholders following the grant. Vesting is conditioned on the director’s continued service to the company through that vesting date.

What does each Indivior (INDV) restricted stock unit represent in this grant?

Each restricted stock unit represents a contingent right to receive one share of Indivior’s common stock. The units convert into shares only upon vesting, assuming the director satisfies the continued-service condition described in the disclosure.

Was there a purchase price paid for the Indivior (INDV) RSUs granted?

No cash purchase price was paid for this grant; the filing lists the transaction price as $0 per share. The RSUs were awarded as equity compensation to the director rather than acquired through an open-market transaction.

Is the Indivior (INDV) director’s ownership direct or through another entity?

The filing shows the 20,645 Indivior shares as directly owned by Daniel A. Ninivaggi. There is no indication in the disclosure or footnotes that the reported holdings are through a trust, partnership, or other indirect ownership vehicle.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:09 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NINIVAGGI DANIEL A

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		3,722(1)	A	$0	20,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Remarks:

	/s/ Jordan Saltzberg, Power of Attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.